Active not recruiting

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

J1O-MC-JZHB - ClinicalTrials.gov - NCT03898791

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
How long will I be in the trial?
Your participation in this trial could last up to 20 months, depending on how you and your tumor respond.
Email
Active not recruiting

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

J1O-MC-JZHB - ClinicalTrials.gov - NCT03898791

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
How long will I be in the trial?
Your participation in this trial could last up to 20 months, depending on how you and your tumor respond.
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage

Participants must have adequate organ function

Participants must have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale

Participants must have discontinued previous treatments for cancer.

Participants must be able to swallow capsules

Participants must NOT

Participants must not be currently enrolled in a clinical study

Participants must not have a serious concomitant systemic disorder

Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C

Participants must not have a significant cardiac condition

Participants must not have previously received an aurora kinase inhibitor

Trial Summary

Conditions the trial is for

Small Cell Lung Cancer

What the trial is testing?

LY3295668 Erbumine

Could I receive a Placebo?

no

Enrollment Goal

64

Trial Dates

July 2019 - December 2021

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage

Participants must have adequate organ function

Participants must have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale

Participants must have discontinued previous treatments for cancer.

Participants must be able to swallow capsules

Participants must NOT

Participants must not be currently enrolled in a clinical study

Participants must not have a serious concomitant systemic disorder

Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C

Participants must not have a significant cardiac condition

Participants must not have previously received an aurora kinase inhibitor

Trial Summary

Conditions the trial is for

Small Cell Lung Cancer

What the trial is testing?

LY3295668 Erbumine

Could I receive a Placebo?

no

Enrollment Goal

64

Trial Dates

July 2019 - December 2021

Trial Phase

1

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Small Cell Lung Cancer Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?